Schedule 13G ownership disclosure

C4 Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 12529R107

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • OrbiMed Advisors LLC

    Shares: 2,174,700.00 · Class: 3.1%

  • OrbiMed Capital LLC

    Shares: 4,655,600.00 · Class: 6.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000543
Form type
SCHEDULE 13G/A
Filer
C4 Therapeutics, Inc.
CIK
CIK 1662579
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub